8-K: Rallybio Halts RLYB212 Development After Phase 2 Trial Fails to Meet Target Concentrations

Rallybio discontinues its RLYB212 program for FNAIT prevention due to unfavorable pharmacokinetic data from a Phase 2 clinical trial, shifting focus to RLYB116 and other pipeline assets.

Summary

• Rallybio Corporation has decided to discontinue the development of RLYB212, a program aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
• This decision was based on pharmacokinetic (PK) data from the Phase 2 clinical trial, which showed that the RLYB212 dose regimen could not achieve the predicted target concentrations or the minimum concentration required for efficacy.
• The Phase 2 trial assessed the PK and safety of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT.
• The second trimester PK results from the sentinel participant showed that RLYB212 failed to reach the predicted target concentrations of 6 ng/mL to 10 ng/mL, and also fell short of the minimum target concentration of 3 ng/mL.
• Rallybio will now focus on advancing RLYB116, a once-weekly C5 inhibitor, and its preclinical programs, including REV102 and RLYB332.
• The company expects to initiate a confirmatory PK/PD study for RLYB116 in the second quarter of 2025, with data readouts expected in the second half of 2025.
• REV102, an ENPP1 inhibitor, entered IND-enabling studies in the first quarter of 2025, with a Phase 1 study planned for 2026.
• Preclinical data for REV102 in a model of later-onset HPP is expected in the second half of 2025.
• RLYB332, a long-acting matriptase-2 antibody, has shown promising preclinical data and is being prepared for future development.

Sentiment

Score: 4

Explanation: The document reports the discontinuation of a clinical program, which is negative. However, the company is shifting focus to other pipeline assets, which provides some optimism. Overall, the sentiment is slightly negative.

Positives

• Rallybio is advancing RLYB116, a C5 inhibitor, with a confirmatory PK/PD study planned for the second quarter of 2025.
• REV102, an ENPP1 inhibitor, entered IND-enabling studies in the first quarter of 2025, with a Phase 1 study planned for 2026.
• RLYB332, a long-acting matriptase-2 antibody, has shown promising preclinical data.
• The company is focused on creating shareholder value by advancing its portfolio of potentially best-in-class assets for patients with rare diseases.

Negatives

• The RLYB212 program for FNAIT prevention has been discontinued due to the inability to achieve target concentrations in the Phase 2 trial.
• The Phase 2 trial results significantly deviated from the predicted range, and there is an absence of empiric data to further inform dose adjustment.

Risks

• The failure of the RLYB212 program may impact investor confidence.
• The development of RLYB116, REV102, and RLYB332 are subject to the risks and uncertainties associated with clinical trials and regulatory approvals.
• Competition from other biotechnology and pharmaceutical companies could impact the success of Rallybio's pipeline.

Future Outlook

Rallybio is focused on advancing its pipeline of assets, including RLYB116, REV102, and RLYB332, with data readouts and study initiations expected in the coming months and years.

Management Comments

• 'We are disappointed by the PK results of the RLYB212 Phase 2 trial,' said Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• 'Given that the results significantly deviated from the predicted range and the absence of empiric data to further inform dose adjustment, the risk/benefit no longer supports continued dosing, and we will discontinue RLYB212 development.'
• 'Rallybio remains steadfast in our mission to develop transformative therapies.'

Industry Context

The discontinuation of RLYB212 highlights the challenges in drug development, particularly in rare diseases. Rallybio's focus on RLYB116, a C5 inhibitor, aligns with the growing interest in complement-mediated therapies. The company's pipeline also includes programs targeting hypophosphatasia and iron overload, addressing unmet needs in these areas.

Comparison to Industry Standards

• Rallybio's RLYB116, a C5 inhibitor, is similar to Alexion Pharmaceuticals' Soliris and Ultomiris, which are also C5 inhibitors used to treat complement-mediated diseases.
• However, RLYB116 is designed for once-weekly subcutaneous injection, potentially offering a more convenient administration compared to Soliris and Ultomiris.
• The development of REV102, an ENPP1 inhibitor, is similar to efforts by other companies to target hypophosphatasia, such as Ultragenyx Pharmaceutical's Crysvita.
• Rallybio's RLYB332, a long-acting matriptase-2 antibody, aims to address iron overload, a condition also targeted by other companies developing iron chelators and hepcidin mimetics.

Stakeholder Impact

• Shareholders may be concerned about the discontinuation of the RLYB212 program.
• Patients with FNAIT will not have access to RLYB212 as a potential treatment option.
• Employees involved in the RLYB212 program may be affected by the discontinuation.

Next Steps

• Initiate dosing in the RLYB116 confirmatory clinical pharmacokinetic/ pharmacodynamic (PK/PD) study in the second quarter of 2025.
• Continue safety follow-up of the sentinel participant in the RLYB212 Phase 2 trial.
• Advance REV102 into a Phase 1 study in 2026.
• Prepare plans for future development of RLYB332.

Key Dates

Keywords

RLYB116, RLYB212, Rallybio, FNAIT, REV102, RLYB332, Clinical Trial, Pharmacokinetic, Rare Diseases, Biotechnology